<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04211766</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006100</org_study_id>
    <secondary_id>NCI-2019-07435</secondary_id>
    <secondary_id>RG1006100</secondary_id>
    <secondary_id>R21CA245456</secondary_id>
    <secondary_id>10327</secondary_id>
    <nct_id>NCT04211766</nct_id>
  </id_info>
  <brief_title>Fiber and Fish Oil Supplements for the Prevention of Colorectal Cancer</brief_title>
  <official_title>Diet and the Colonic Exfoliome: A Novel, Non-Invasive Approach to Testing Interventions in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas A&amp;M University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how fiber and fish oil supplements affect the metabolism and activities of&#xD;
      colon cells in healthy individuals. Diet is an important risk factor for colorectal cancer,&#xD;
      and several dietary components important in colorectal cancer prevention are modified by gut&#xD;
      microbial metabolism. Giving fiber and fish oil supplements may inhibit the growth of gut&#xD;
      cells and ultimately reduce risk of colorectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants are randomized to receive two dietary interventions in assigned random order.&#xD;
      They either receive the dietary fiber supplement and fish oil supplement orally (PO) daily or&#xD;
      they receive a fiber control and corn oil supplement daily for 30 days during the first&#xD;
      intervention period. Then they enter a washout period for 60 days when they do not receive&#xD;
      any treatment. After that they complete the second intervention period during which they&#xD;
      receive the other intervention.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 5, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in mRNA expression profiles in the exfoliome</measure>
    <time_frame>Baseline to 2 years</time_frame>
    <description>Poly A+ RNA will be isolated from exfoliated cells in stool, and libraries generated from stool RNA will be sequenced on an Illumina HiSeq 2500 platform.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Healthy Subject</condition>
  <arm_group>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a fiber supplement daily and a fish oil supplement PO daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group II.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive a fiber supplement placebo daily and a fish oil supplement placebo daily on days 1-30. Participants enter a washout period for at least 60 days and then crossover to Group I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Dietary Fiber</intervention_name>
    <description>Given fiber supplement</description>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <other_name>Fiber</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish Oil</intervention_name>
    <description>Given fish oil supplement</description>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <other_name>Oil, Fish</other_name>
    <other_name>Seafood Oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given fiber supplement placebo</description>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given fish oil supplement placebo (corn oil)</description>
    <arm_group_label>Group I (supplemental fiber and fat followed by placebo)</arm_group_label>
    <arm_group_label>Group II (placebo followed by supplemental fiber and fat)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy&#xD;
&#xD;
          -  Normal-overweight (body mass index [BMI] of 18-30 kg/m^2)&#xD;
&#xD;
          -  Women will be postmenopausal, with no menstrual period in 12 months&#xD;
&#xD;
          -  Non-smoking&#xD;
&#xD;
          -  Consume fiber intakes of less than &lt; 20 g/d&#xD;
&#xD;
          -  White blood cell count 3,000-11,000/mm^3&#xD;
&#xD;
          -  Platelet count 100,000-400,000 mm^3&#xD;
&#xD;
          -  Hematocrit 33-50% (women); 36-50% (men)&#xD;
&#xD;
          -  Bilirubin 0.2-1.3 mg/dL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) 0-35 U/L&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) 0-40 U/L&#xD;
&#xD;
          -  Alkaline phosphatase 20-125 U/L&#xD;
&#xD;
          -  Creatinine =&lt; 1.2 mg/dL&#xD;
&#xD;
          -  Potassium 3.5-5.0 mmol/L&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic medical illness, history of gastrointestinal disorders (e.g., ulcerative&#xD;
             colitis, Crohn disease, celiac sprue, hereditary nonpolyposis colorectal cancer&#xD;
             [HNPCC], familial adenomatous polyposis, pancreatic disease, previous gastrointestinal&#xD;
             resection, radiation or chemotherapy, and cancer (other than non-melanoma skin cancer)&#xD;
&#xD;
          -  Weight change greater than 4.5 kg within past year&#xD;
&#xD;
          -  Oral or intravenous (IV) antibiotic use within the past 3 months&#xD;
&#xD;
          -  Regular use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
          -  Smoking or use of cannabis products&#xD;
&#xD;
          -  Known allergy to fish&#xD;
&#xD;
          -  Intention to relocate out of study area within next 4 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johanna Lampe</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johanna Lampe</last_name>
    <phone>206-667-6580</phone>
    <email>jlampe@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Lampe</last_name>
      <phone>206-667-6580</phone>
      <email>jlampe@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Johanna Lampe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 26, 2019</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Colon</keyword>
  <keyword>Rectum</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

